pSivida (NSDQ:PSDV) said yesterday that the FDA plans to review the company’s application for its drug-releasing ocular insert, Durasert. The product is designed to provide three years of treatment for patients with posterior segment uveitis.
The U.S. regulatory agency is slated to decide whether or not to approve pSivida’s new drug application by Nov. 5.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA to review pSivida’s ocular drug-delivery system appeared first on MassDevice.
from MassDevice http://ift.tt/2psmCfv
Cap comentari:
Publica un comentari a l'entrada